Antibody Response against SARS-CoV-2 Following ChAdOx1(Astezeneca AZD 1222) Vaccine in Health Care Workers in a Tertiary Care Hospital in India

Antibody Response against SARS-CoV-2 Following ChAdOx1(Astezeneca AZD 1222) Vaccine in Health Care Workers in a Tertiary Care Hospital in India

BACKGROUND: The ChAdOx1 nCoV-19 vaccine against COVID-19 is a two-dose vaccine spread 3 to 4 weeks apart. This study aims to ascertain the antibody response to each dose with respect to age, previous infection status etc. METHODS: Baseline total COVID-19 antibody level was ascertained using Siemens...

Full description

Bibliographic Details
Main Authors:	Felice FAIZAL, Rajneesh JOSHI, R CHATTERJEE, Ankur AHUJA
Format:	Article
Language:	English
Published:	Media Med Publicis 2021-09-01
Series:	Modern Medicine
Subjects:	covid-19 vaccine chadox1 ncov-19 influenza vaccines vaccination and immunity
Online Access:	https://medicinamoderna.ro/wp-content/uploads/2021/09/Antibody-Response-against-SARS-CoV-2-Following-ChAdOx.pdf

Similar Items

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
by: Salma Al Bahrani, et al.
Published: (2021-09-01)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
by: Evangelos Terpos, et al.
Published: (2021-07-01)

Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2
by: Sang Won Lee, et al.
Published: (2021-09-01)

Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222)
by: Gustavo C. Román, et al.
Published: (2021-04-01)

Using the Bradford-Hill criteria to assess causality in the association between CHADOX1 NCOV-19 vaccine and thrombotic immune thrombocytopenia
by: C Raina MacIntyre
Published: (2021-04-01)

A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy
by: Raffaele Palladino, et al.
Published: (2021-06-01)

Successful surgical-multimodal treatment for vaccine-induced complete splanchnic vein thrombosis after ChAdOx1 nCoV-19 vaccination
by: Brennfleck, F.W, et al.
Published: (2022)

BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees
by: Ahmed N. Alghamdi, et al.
Published: (2021-10-01)

Possible side effects of ChAdOx1 nCov-19 vaccine in patients with sickle cell disease
by: Salam Alkindi, et al.
Published: (2021-09-01)

Myasthenia gravis with ocular symptoms following a ChAdOx1 nCoV-19 vaccination: A case report
by: Kang, M.C, et al.
Published: (2022)

Adverse Effects of the COVID-19 Vaccine Reported by Lecturers and Staff of Kabul University of Medical Sciences, Kabul, Afghanistan
by: Azimi M, et al.
Published: (2021-10-01)

Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report
by: Ekachai Singhatiraj, et al.
Published: (2021-09-01)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
by: Alexandre Vallée, et al.
Published: (2021-08-01)

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2
by: Sebastian Havervall, et al.
Published: (2021-08-01)

A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population
by: Chinonyerem O. Iheanacho, et al.
Published: (2021-08-01)

Is the heparin-induced thrombocytopenia-like syndrome associated with ChAdOx vaccine related to the vaccine itself or to an autoimmune reaction to severe acute respiratory syndrome 2 coronavirus: insights and implications from previous reports in infected cases?
by: A. AbdelMassih, et al.
Published: (2021-05-01)

Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States
by: Abanoub Riad, et al.
Published: (2021-06-01)

Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
by: Louise Benning, et al.
Published: (2021-08-01)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
by: Argimon, J.M, et al.
Published: (2022)

Effects of Short-Term Corticosteroid Use on Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine
by: Jinyoung Yang, et al.
Published: (2021-09-01)

Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50
by: Feng, S., et al.
Published: (2022)

Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19
by: Rajashri Bezbaruah, et al.
Published: (2021-04-01)

Adverse Effects on Work and Daily Life Interference among Healthcare Workers after the First and Second ChAdOx1 and BNT162b2 COVID-19 Vaccine Doses
by: Chulyong Park, et al.
Published: (2021-08-01)

Vaccine‐induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine–A case report
by: Bader Al Rawahi, et al.
Published: (2021-08-01)

Cerebral Venous Sinus Thrombosis Following COVID-19 Vaccination: A Systematic Review
by: Agarwala, P., et al.
Published: (2022)

Diffuse prothrombotic syndrome after ChAdOx1 nCoV-19 vaccine administration: a case report
by: Nicole Ceschia, et al.
Published: (2021-10-01)

Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus
by: Sergio Utrilla-Trigo, et al.
Published: (2020-06-01)

COVID-19 vaccines: Current evidence and considerations
by: Alireza Tavilani, et al.
Published: (2021-12-01)

Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2
by: Ilir Alimehmeti
Published: (2021-01-01)

Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines
by: Edmund G. Wee, et al.
Published: (2021-06-01)

Rapid whole‐blood assay to detect SARS‐CoV‐2‐specific memory T‐cell immunity following a single dose of AstraZeneca ChAdOx1‐S COVID‐19 vaccine
by: Katie E Lineburg, et al.
Published: (2021-01-01)

Palatal petechiae: an uncommon oral adverse effect of COVID-19 vaccine
by: Bhawna Sayare, et al.
Published: (2021-09-01)

Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination – A Case Report
by: Martin Koch, et al.
Published: (2021-07-01)

COVID-19 challenges and its therapeutics
by: Sabi Ur Rehman, et al.
Published: (2021-10-01)

Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers
by: Miloslav Klugar, et al.
Published: (2021-08-01)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
by: César López-Camacho, et al.
Published: (2020-06-01)

Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)
by: Assanatham, M., et al.
Published: (2022)

A brief review of the latest pharmacological treatments of COVID-19
by: Seyed Parsa Eftekhar, et al.
Published: (2020-11-01)

Proteome Organization of COVID-19: Illustrating Targets for Vaccine Development
by: Alok Bharadwaj, et al.
Published: (2020-05-01)

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination
by: Gerardo Casucci, et al.
Published: (2021-06-01)